CDP323

DRUG2 trials

Sponsors

UCB Pharma

Conditions

Multiple SclerosisRelapsing Multiple Sclerosis

Phase 1

CDP323 Biomarker Study

CompletedNCT00726648

UCB PharmaRelapsing Multiple Sclerosis

Start: 2008-07-31End: 2009-03-31Updated: 2011-09-12

Phase 2

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

TerminatedNCT00484536

UCB PharmaMultiple Sclerosis

Start: 2007-05-31End: 2010-07-31Updated: 2011-09-12

Related Papers

Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.

2013-03-058 citations